Nuveen LLC bought a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 428,109 shares of the company's stock, valued at approximately $179,784,000. Nuveen LLC owned approximately 0.53% of IDEXX Laboratories at the end of the most recent quarter.
Several other hedge funds have also added to or reduced their stakes in IDXX. GAMMA Investing LLC boosted its holdings in IDEXX Laboratories by 59,810.7% in the first quarter. GAMMA Investing LLC now owns 918,431 shares of the company's stock worth $3,856,950,000 after acquiring an additional 916,898 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in IDEXX Laboratories by 58.3% in the first quarter. Principal Financial Group Inc. now owns 1,126,002 shares of the company's stock worth $472,865,000 after acquiring an additional 414,802 shares in the last quarter. Alyeska Investment Group L.P. bought a new stake in IDEXX Laboratories in the fourth quarter worth $156,412,000. BNP Paribas Financial Markets boosted its holdings in IDEXX Laboratories by 221.3% in the fourth quarter. BNP Paribas Financial Markets now owns 441,319 shares of the company's stock worth $182,459,000 after acquiring an additional 303,966 shares in the last quarter. Finally, Montrusco Bolton Investments Inc. bought a new stake in IDEXX Laboratories in the first quarter worth $120,008,000. 87.84% of the stock is owned by institutional investors.
IDEXX Laboratories Stock Down 0.9%
IDEXX Laboratories stock opened at $652.11 on Tuesday. The stock has a market cap of $52.17 billion, a PE ratio of 54.30, a price-to-earnings-growth ratio of 4.25 and a beta of 1.49. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $688.12. The stock has a fifty day moving average of $547.98 and a 200 day moving average of $481.51.
IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported $3.63 EPS for the quarter, beating analysts' consensus estimates of $3.28 by $0.35. The company had revenue of $1.11 billion during the quarter, compared to analysts' expectations of $1.06 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%. IDEXX Laboratories's revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.44 earnings per share. As a group, sell-side analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.
Wall Street Analyst Weigh In
Several equities research analysts have commented on the company. Stifel Nicolaus set a $640.00 target price on IDEXX Laboratories in a report on Monday, August 4th. Leerink Partners increased their price objective on IDEXX Laboratories from $580.00 to $600.00 and gave the company an "outperform" rating in a research report on Thursday, July 17th. Piper Sandler reaffirmed a "neutral" rating and set a $700.00 price objective (up from $510.00) on shares of IDEXX Laboratories in a research report on Monday. Morgan Stanley set a $722.00 price objective on IDEXX Laboratories and gave the company an "overweight" rating in a research report on Tuesday, August 5th. Finally, BTIG Research increased their price objective on IDEXX Laboratories from $545.00 to $785.00 and gave the company a "buy" rating in a research report on Tuesday, August 5th. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, IDEXX Laboratories currently has an average rating of "Moderate Buy" and a consensus target price of $644.67.
Read Our Latest Stock Analysis on IDEXX Laboratories
Insider Transactions at IDEXX Laboratories
In related news, Director M Anne Szostak sold 1,260 shares of the company's stock in a transaction on Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total transaction of $645,548.40. Following the completion of the sale, the director owned 1,801 shares in the company, valued at approximately $922,724.34. This represents a 41.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jonathan Jay Mazelsky sold 29,260 shares of the company's stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $631.98, for a total value of $18,491,734.80. Following the sale, the chief executive officer owned 83,311 shares of the company's stock, valued at approximately $52,650,885.78. This trade represents a 25.99% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 47,120 shares of company stock worth $29,457,738 in the last three months. 0.98% of the stock is owned by insiders.
IDEXX Laboratories Profile
(
Free Report)
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
See Also
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider IDEXX Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.
While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report